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MPTThe mechanism of interaction of Cr(VI) with isolated rat liver mitochondria was investigated in this study.
The results suggest that Cr(VI) induces the opening of the membrane permeability transition pore (MPT).
The phenomenon is cyclosporine-sensitive and is in agreement with the cyclosporine-sensitive apoptosis
observed in the cells incubated with this compound. Moreover the action of Cr(III), that is formed in the cells
by a reduction of Cr(VI), has been also analysed. The results obtained demonstrated that the Cr(III) does not
induce the opening of the MPT in isolated mitochondria, but it has a protective effect in preventing Cr(VI)
MPT opening. Therefore, these results suggest that apoptosis is regulated by a balance between Cr(VI)
accumulation in the cytoplasm and Cr(III) formation.: +39 041 234 8593.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.Many “in vitro” studies regarding the interactions of Cr(VI) with
cellular and sub-cellular structures have been performed directed to
discover the biological-molecular mechanism responsible for the high
toxicity of this element [1–10].
Among the numerous cellular investigations carried out, two
significant findings stand out:
- Cr(VI) enters into the cell (by means of a carrier-mediated
mechanism). Cell apoptosis is subsequently induced and the
phenomenon is inhibited by cyclosporine A [1,4,6,9,39,41];
- Once inside the cell, the Cr(VI) is reduced to Cr(III) [2,3,5,8].
However, these experiments do not clarify whether the apoptosis
is induced by Cr(VI) or by Cr(III) since both compounds are present in
the cell. In order to clarify this point, the interactions of both Cr(VI)
and Cr(III) with isolated mitochondria were investigated in the
present study since mitochondria are involved in all apoptosis
mechanisms, and the cyclosporine-sensitive cell apoptosis is corre-
lated with the opening of a mitochondrial pore (a MPT cyclosporine-
sensitive pore) [11,12].
The interactions of chromium as Cr(VI) with isolated plants and
animal mitochondria were previously studied [7,10], but the conclu-
sions did not clarify the above cited problem. In particular, the
opening of themembrane pore and the cyclosporine-sensitivity of this
phenomenon, which is the key experiment for determining the
involvement of mitochondria, has never been taken into account
[7,10]. This study intends to demonstrate that only Cr(VI) forminduces the opening of the mitochondrial cyclosporine-sensitive pore,
while Cr(III) has no effect on this process, but, conversely, it seems to
have a protective effect against the opening of the pore induced by Cr
(VI).
In mitochondria, the free energy arising from the oxidation of the
substrates by molecular oxygen is utilized to form ATP from ADP. The
oxidation of the substrates leads to the production of NADH and
FADH2 which triggers the electron flux along the mitochondrial
respiratory chain (RC). The electron flow in the RC gives rise to a
proton extrusion, that in turn gives rise to a ΔΨ (electrical gradient)
and to a ΔpH (chemical gradient) which constitute the proton-motive
force (p.m.f.=ΔΨ+ΔpH), driving the ATP synthesis [15]. This
mechanism is possible by the fact that the mitochondrial membrane
is not permeable to protons. Therefore, any mechanism which causes
an enhancement of the membrane permeability to protons causes a
corresponding cell damage. For this reason, the mitochondria were
investigated as a possible target for many toxic compounds.
The existence of a membrane pore in mitochondria has been
demonstrated by many authors [11,12]. The opening of this pore
(membrane permeability transition pore, MPT), which is inhibited by
cyclosporine A and induced by many compounds, such as metals and
organometals [16–23], allows the transit of large molecules up to a
size of about 1.5 kD [11,12]. Some evidences suggest that the opening
of this pore is correlated with a particular cell death, i.e. the apoptosis
[11,12]. The pore opening is routinely evidenced by means of swelling
experiments. Mitochondrial swelling is caused by a colloid-osmotic
effect: in isolated mitochondria suspended in a sucrose medium, the
occurring of the MPT allows the sucrose entry. This phenomenon is
accompanied by the entrance of water and not by an equivalent
extrusion of solutes, in particular endogenous proteins (the colloid
Fig. 2. Cr(III) effect on mitochondrial swelling. A) successive additions of 50 µM Cr3+ ,
(added as CrCl3 from a stock solution of 0.02 M CrCl3 in water) up to a final
concentration of 0.2 mM (each arrow indicates the addition of 50 μM Cr3+) do not
induce mitochondrial swelling. B) successive additions of 50 µM Cr(VI) to the
resuspending medium containing 0.1 mM Cr3+, up to a final concentration of 0.2 mM
(each arrow indicates the addition of 50 μM CrO42−) do not induce a mitochondrial
swelling.
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be monitored by means of absorbance quenching at a wavelength of
540 nm [11,12].
Fig. 1A (trace a) shows the swelling induced by CrO42− added as
K2CrO4 to isolated mitochondria. The swelling is inhibited by
cyclosporine A, (Fig. 1A, trace b, dotted line). This situation suggests
that the phenomenon (swelling) is due to the opening of the MPT
pore. This statement is supported by the results of the experiments
reported in Fig. 1 B (trace a), which shows the swelling induced by
phenylarsine oxide (Phe As), a classical inducer of the pore opening
[24,25]; it also illustrates the cyclosporine inhibition, (Fig. 1 B, trace b,
dotted line).
Fig. 2A shows the lack of effect of Cr3+ added as CrCl3 on the
mitochondrial swelling since this phenomenonwasnot observedup to a
concentration of 0.2 mMCr3+. On the contrary, it appears that Cr3+ has
aprotective effect against the swelling inducedbyCrO42−, since the latter
compound, in thepresence of Cr3+does not induce appreciable swelling
(Fig. 2 B).
The mechanism of Cr(VI) transport into the cells and the
subsequent effects (i.e. respiratory parameters) were already exten-
sively studied [2,3,5,8]. Based on the appearance of the paramagnetic
Cr(III) [8] (monitored by means of electron spin resonance), or by
means of spectrophotometric techniques [26], it was concluded that
the Cr(VI) enters the cell by means of a carrier-mediated mechanism,
and that it is reduced inside the cell to Cr(III). Some authors, however,
have hypothesized the formation of Cr(V) [27] as intermediate
compound.
Furthermore, even if the mechanism of apoptosis is not fully
understood and its interpretation is controversial, many authors have
concluded that Cr(VI) induces cell apoptosis [1,4,6,9,39,41]. This
conclusion is strongly supported by the evidence of the involvement
of mitochondria in the process [1,9,12,28], in particular, by the
cyclosporine-sensitivity [1,12,28] and cytochrome c release [1]
correlated with the respiratory rate inhibition [39,40], as well as by
the caspase-3 activity enhancement [9,41].
Once established these points, an important question remains
open: since Cr(VI) can be reduced to Cr(III), which oxidative status of
chromium is responsible for the apoptosis induction?Fig. 1. Cr(VI) induces swelling in isolated rat liver mitochondria. A) Mitochondrial
swelling measured after successive additions of CrO42− (added as K2CrO4, from a stock
solution of 0.1 M K2CrO4 in water) up to a final concentration of 0.1 mM (each arrow
indicates the addition of 20 μM CrO42−) to the mitochondrial suspension in the absence
(trace a), or presence of 1 γ cyclosporine (trace b, dotted line) (1 γ=1microgram).
B) Mitochondrial swelling induced by 20 μM phenylarsine oxide (Phe As) in the
absence (trace a) or presence of 1 γ cyclosporine (trace b, dotted line). Medium com-
position: 0.25 M sucrose, 10 mM Hepes–Mops, pH 7.4, 1 mM MgCl2, 1 mM sodium
succinate, 0.2 mM EGTA. Mitochondria, final concentration, 0.5 mg protein/ml. Mito-
chondria from rat liver were prepared following the standard procedures [13] and the
protein concentration assayed according to the Lowry's method [14]. Swelling experi-
ments: the mitochondria (final concentration 0.5 mg/ml) were added to the resus-
pending medium (2.5 ml) and the apparent absorbance changes were measured in a
Jenway 6400 spectrophotometer, under stirring conditions at room temperature. The
instrument was then adjusted to zero absorbance and the swelling monitored as
absorbance decrease at 540 nm. Medium composition: 0.25 M sucrose, 10 mM Hepes–
Mops, pH 7.4, 1 mM MgCl2, 1 mM succinate, 0.1 mM EGTA.In this paper, it has been confirmed that the mitochondria are
responsible for the cell apoptosis occurring upon their incubation
with Cr(VI), since both mitochondrial swelling and cells apoptosis are
cyclosporine-sensitive. Furthermore the present experiments clarify
that the inducer of the mitochondrial cyclosporine-sensitive swelling
is the Cr(VI), while Cr(III) has a protective effect on this process.
As a consequence, it has been proposed that the mitochondrial
pore and the apoptosis should be regulated by a balance between Cr
(VI) accumulation in the cell and Cr(III) formation.
The capacity of Cr(VI) to induce a cyclosporine-sensitive swelling
is important to explain the consequent apoptosis. In fact, taking into
account the literature data, in particular those reported in [2] and [7],
it is possible to conclude that the effect of Cr(VI) (i.e. pore opening)
requires the minimal effective toxicological dose. In this regard,
reference [2] provides two fundamental results:
- the reduction of Cr(VI) to Cr(III) occurs at the first site of the
mitochondrial RC (by means of NADH-linked substrates)
- the inhibition of the RC requires very high concentration of Cr(VI),
about 3.5 mM. The same authors [2] report that Cr(VI) is not an
inhibitor of the ATPase. As above discussed, the ATP synthesis [15]
requires the involvement of the RC and ATPase activity. In
addition, the chemiosmotic hypothesis [15] requires a non
permeability to protons. An enhancement of the membrane
permeability to protons can occur by means of the opening of a
pore or by means of a protonophore. As regards this last
mechanism, the protonophores must be a weak acid and do not
require a carrier transport [15]. H2CrO4, which is formed upon
addition of K2CrO4, is a weak acid, but it is not permeant, as
demonstrated by the requirement of a non specific carrier to enter
the mitochondrial matrix [8]. The remaining possibility is that, in
order to inhibit the ATP synthesis, the dose necessary for the
opening of the mitochondrial pore is lower than that necessary
(3.5 mM!) to inhibit the RC. This situation effectively occurs,
although it is not easy to quantify the Cr(VI) concentration
necessary for the MPT opening, (the apparent opening measured
as swelling is time-dependent and the response is not linear). On
the basis of the results reported here, it is possible to conclude that
this dose is below 0.1 mM. These data are in agreement with those
reported in [2] and [7], where the ATP synthesis inhibition by Cr
(VI), measured by means of the respiratory parameters, occurs at
the same level range.
As Cr(III) is concerned, it is reported that it inhibits the RC at a
concentration higher than 1 mM. In addition, it has been verified, that
1 mM Cr(III) does not inhibit the ADP-stimulated respiratory rate
(state 3), nor the mitochondrial basal respiration (state 4) thus
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(not shown).
Considering that Cr(III) is not permeant to the biological
membranes [8] and that a quantitative determination of Cr(III) in
the cell, where it is produced, is not easy, it is only possible to
hypothesize that Cr(III) can only interfere with the Cr(VI) induced
apoptosis.
The mechanism concerning the opening of the MPT pore, is very
complicated, as it depends on many concomitant factors and, until
now, an exhaustive explanation of this mechanism has not been given
yet [11,12,28]. The aim of this study is not the investigation on the
molecular mechanism, but a preliminary hypothesis regarding the
role of Cr(VI) and Cr(III) can be proposed.
In the case of divalent metals (and of Al3+, phenylarsine oxide and
oxidising compounds), which are inducers of the cyclosporine-
sensitive swelling, the proposed molecular mechanism was that the
ANT (adenine nucleotide traslocase) (where the metals and the
oxidant agents form an intramolecular cross-linking between the
Cys160 and Cys257 thiol groups) is a target site [17,24,25,29–35].
Recently, this hypothesis regarding the involvement of the ANT
has been strongly attacked and disavowed [36]. The new proposal [37]
suggests that the phosphate carrier (and not the ANT) is the crucial
step responsible for the MPT opening. Being the proposal very recent
(2008), it is not possible to utilize previous hypothesis (since they are
not reference points) in order to compare the behaviour of chromium
with that of other metals and oxidising agents which are inducers of
the MPT opening by means of an interaction with the phosphate
carrier. This can render the pattern more complex. However, taking
into account the presence of thiol groups in the phosphate carrier [38],
it is possible to propose in the case of Cr(VI), an oxidation of the SH
groups to form –S–S– bridges. This should be the step which triggers
subsequent modifications in the phosphate carrier leading to the
opening of the MPT pore. The protective effect of Cr(III) should be due
to a preventive coordinative binding of Cr(III) to the –SH groups
which inhibits the subsequent oxidation by Cr(VI).
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